GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ectin Research AB (XSAT:ECTIN B) » Definitions » Treasury Stock

Ectin Research AB (XSAT:ECTIN B) Treasury Stock : kr0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ectin Research AB Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Ectin Research AB's treasury stock for the quarter that ended in Mar. 2024 was kr0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.


Ectin Research AB Treasury Stock Historical Data

The historical data trend for Ectin Research AB's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ectin Research AB Treasury Stock Chart

Ectin Research AB Annual Data
Trend Aug19 Aug20 Dec22 Dec23
Treasury Stock
- - - -

Ectin Research AB Quarterly Data
Aug19 Aug20 Mar21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ectin Research AB Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.


Ectin Research AB (XSAT:ECTIN B) Business Description

Traded in Other Exchanges
N/A
Address
Pepparedsleden 1, Molndal, SWE, 431 83
Ectin Research AB is a pharmaceutical company developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 engages in the treatment of metastatic bladder cancer, and has also shown potential in other cancers such as breast, colorectal and prostate cancer cells.

Ectin Research AB (XSAT:ECTIN B) Headlines

No Headlines